<DOC>
	<DOCNO>NCT00306787</DOCNO>
	<brief_summary>This study ass safety efficacy one-day famciclovir ( 1000 mg twice day ( b.i.d ) ) reduce duration genital herpes lesion associate symptom compare three-day treatment valacyclovir ( 500 mg capsule b.i.d ) .</brief_summary>
	<brief_title>Efficacy Safety Famciclovir 1-day Treatment Compared 3-day Treatment With Valacyclovir Adults With Recurrent Genital Herpes</brief_title>
	<detailed_description />
	<mesh_term>Herpes Genitalis</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<mesh_term>Famciclovir</mesh_term>
	<mesh_term>2-Aminopurine</mesh_term>
	<criteria>At least 18 year old History least 4 recurrence genital herpes precede 12 month Lesions locate external genitalia anogenital region Willing discontinue suppressive treatment Documented positive herpes simplex virus ( HSV ) General good health , history normal renal function Women childbearing potential use approved form contraceptive Pregnant nursing woman History hypersensitivity famciclovir , valacyclovir , acyclovir Known immunosuppressed Known renal dysfunction Receiving antiherpes therapy Known genital tract disorder Known condition could interfere drug absorption Additional protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Herpes simplex</keyword>
	<keyword>genital herpes</keyword>
	<keyword>famciclovir</keyword>
	<keyword>valacyclovir</keyword>
	<keyword>Recurrent genital herpes</keyword>
</DOC>